Support Pullquote, upgrade to Pro!
(Or just tweet your Pullquote for free!)
With Pullquote Pro, you'll get to:
- share on Facebook
- schedule tweets
- tweet from multiple accounts
- edit quotes
- customize colors
- change fonts
- save and index quotes
- private quotes
Choose a plan: $5/month $50/year (includes free access to any new features)
Recent quotes:
‘Right to Repair for Your Body’: The Rise of DIY, Pirated Medicine
The Microlab is the lab equipment (called a controlled lab reactor or CLR) that you use to actually make medicine, using the suggested reaction pathways given by Chemhacktica. Costs for the materials to build this are between $300 and $500, depending on the features you want. Four Thieves has released detailed instructions about how to build and use the Microlab, as well as software that will make it run.
‘Right to Repair for Your Body’: The Rise of DIY, Pirated Medicine
So Four Thieves Vinegar Collective set out to teach people how to make their own version of Sovaldi. Chemists at the collective thought the DIY version would cost about $300 for the entire course of medication, or about $3.57 per pill. But they were wrong.
Is Doctor Pay Too High? NIH Pulls Plug on Misinfo Research; FDA and EPA Butt Heads | MedPage Today
Previous NIH Director Francis Collins, MD, PhD, publicly proposed the project idea in 2021, saying, "We basically have seen the accurate medical information overtaken, all too often, by the inaccurate conspiracies and false information on social media," and "I do think we need to understand better how -- in the current climate -- people make decisions."
The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated | Genetics in Medicine
Until very recently, the fragmented distribution of patients across institutions hindered the discovery of new rare diseases. Clinicians working with a single, isolated patient could steadily eliminate known disorders but do little more. Families would seek clinicians with the longest history and largest clinic volume to increase their chances of finding a second case, but what does a physician do when N = 1 or if the phenotype is inconsistent across patients? These challenges are driving an increase in the use of NGS. Yet this technological advance presents new challenges of its own. Perhaps the most daunting, in our opinion, is the inability to share sequencing data quickly and universally. Standards and bioinformatic tools are needed that allow for a national repository where families or scientists can bring clinical results and NGS data for comparison. This challenge can be circumvented by tools already created for and by the Internet and social media.
